文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤放疗物理与技术

宫颈癌寡转移与寡复发治疗模式调查:EMBRACE研究网络

Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network.
PubMed 文献 · Radiother Oncol · 2020-11-02

结果显示,90%中心报告新发寡转移发病率低于5%,77.3%推荐立体定向消融放疗,90%具备立体定向放疗能力并愿参与临床试验,但实践存在差异,亟需联合临床方案。

要点

  • 90%中心报告新发寡转移宫颈癌发病率低于5%,寡复发比例为5-10%。
  • 77.3%中心推荐立体定向消融放疗用于寡转移,90%具备立体定向放疗能力。
  • 68.2%推荐放化疗联合近距离放疗,31.8%考虑额外全身治疗。

核心结论

  • 尽管当代实践存在差异,相当比例EMBRACE中心在寡转移和寡复发场景中考虑高剂量放疗,但亟需联合临床方案和前瞻性研究。

研究设计与样本

  • EMBRACE研究组参与中心填写17项电子问卷,包含病例相关问题,调查新发寡转移和原发治疗完成后寡复发的管理。
  • 问卷通过电子邮件发送,2周调查期内两轮提醒,在线问卷要求完成所有问题,结果以比例和汇总统计呈现。

主要发现

  • 所有中心均倾向治疗新发寡转移场景中的盆腔病灶,但分割方案不同。
  • 68.2%推荐放化疗联合近距离放疗,31.8%考虑额外全身治疗。
  • 77.3%中心推荐立体定向消融放疗用于寡转移;野外淋巴结复发中63.7%考虑根治性治疗,野内复发中59%倾向姑息治疗。
  • 90%中心具备立体定向放疗能力,并愿考虑针对寡转移和寡复发的临床试验。

关键数值与推荐

  • 90%中心报告新发寡转移宫颈癌发病率低于5%。
  • 寡复发比例为5-10%。
  • 68.2%推荐放化疗联合近距离放疗,31.8%考虑额外全身治疗。
  • 77.3%推荐立体定向消融放疗用于寡转移。
  • 野外淋巴结复发63.7%考虑根治性治疗,野内复发59%倾向姑息治疗。

临床怎么用

  • 新发寡转移宫颈癌的盆腔病灶可考虑放疗,但分割方案需个体化。
  • 寡转移灶可考虑立体定向消融放疗,野外淋巴结复发可考虑根治性治疗。
  • 寡复发和寡转移场景的高剂量放疗应用需结合中心能力和临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the metastatic or recurrent cervical cancer, systemic chemotherapy constitutes the main treatment. Though there is an increasing use of high dose external radiation and brachytherapy in the metastatic setting, no consensus exists. METHODS: A 17-item survey was designed with additional case-based questions to explore present management of oligo-metastatic and oligo-recurrent cervix cancer within EMBRACE research group participating sites. The questions were designed to elicit prevailing practices in the management of de-novo oligo-metastasis and oligo-recurrent setting after completing the primary treatment of cervix cancer. The survey was sent electronically with two rounds of email reminders to respond over a 2-week survey period. The online survey was designed such that it was mandatory to complete all questions. The responses were recorded and results were summarized as proportions and summary statistics were generated. RESULTS: Twenty-two centers responded to this survey. A majority (90%) of respondents reported a low incidence of de-novo oligo-metastatic cervical cancer in their practice (<5%), with a higher proportion of patients with oligo-recurrence after completing primary treatment (5-10%). All responding sites preferred to treat pelvic disease in the de-novo oligo-metastatic setting albeit with different fractionation regimens. While 68.2% of respondents recommended chemo-radiation and brachytherapy, 31.8% considered additional systemic therapy. Overall 77.3% centers recommended the use of stereotactic ablative radiation therapy to oligo-metastasis. For out-of-field nodal recurrences, 63.7% of respondents considered treating with curative intent, while 59% preferred treating in-field recurrence with palliative intent. A vast majority of the participating centers (90%) have stereotactic radiation therapy capacity and would consider a clinical trial addressing oligo-metastatic and oligo-recurrent cervical cancer. CONCLUSION: Although contemporary practice is variable, a substantial proportion of EMBRACE centers consider high dose radiation in de-novo metastatic and oligo-recurrence settings. However, there is clear need for a joint clinical protocol and prospective studies to address the role of high dose radiation within oligo-recurrent and oligo-metastatic scenarios.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chopra S, Mangaj A, Sharma A, et al. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network. Radiother Oncol. 2020. PMID: 33144247. doi:10.1016/j.radonc.2020.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。